Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorInsel Gruppe AG, University Hospital Bern

About this trial

Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.

Eligibility criteria

Qualifiers

None

Disqualifiers

Patients with major intra-cranial trauma

Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography

More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)

Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)

Trial design

Treatments tested in this trial

  • 0.9% Sodium-chloride
  • Ringer's Lactate

Treatment groups

320 Participants
are divided into 2 treatment groups